Nebenwirkungen · Adcetris
ADCETRIS 50 mg powder for concentrate for solution for infusion. · Abschnitt 4.8 · PDF-Seite 19
HOS-126075 · Präparat HOS-096209
In the clinical trial of ADCETRIS as combination therapy with CHP, treatment emergent neuropathy occurred in 52% of the population; peripheral motor neuropathy occurred in 9% of patients. Peripheral neuropathy led to treatment discontinuation in 1%, dose reductions in 7% and dose delays in < 1% of patients. For patients who experienced peripheral neuropathy the median time of onset was 9.1 weeks. Patients who discontinued due to peripheral neuropathy received a median of 5 doses of ADCETRIS + CHP (A+CHP) before discontinuation of one or more agents.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-20T10:51:00Z · SHA-256 a80608da289c54a95c6f3ae56a63c85084ccf90e8e43e395dd22479d252877cb · Passage 9f484997e4ac991db14c9f3b817f8c4d43b0334b9729254bb92d16e4a63363f5 · Zeichen 15710–16265 im Abschnitt